| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8906938 | CHEMOCENTRYX | C5aR antagonists |
Dec, 2029
(5 years from now) | |
| US8445515 | CHEMOCENTRYX | C5aR antagonists |
Feb, 2031
(6 years from now) | |
| US11603356 | CHEMOCENTRYX | Amorphous form of a complement component C5a receptor |
May, 2041
(17 years from now) | |
Tavneos is owned by Chemocentryx.
Tavneos contains Avacopan.
Tavneos has a total of 3 drug patents out of which 0 drug patents have expired.
Tavneos was authorised for market use on 07 October, 2021.
Tavneos is available in capsule;oral dosage forms.
Tavneos can be used as an adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids.
Drug patent challenges can be filed against Tavneos from 07 October, 2025.
The generics of Tavneos are possible to be released after 29 May, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-377) | Oct 07, 2028 |
| New Chemical Entity Exclusivity(NCE) | Oct 07, 2026 |
Drugs and Companies using AVACOPAN ingredient
NCE-1 date: 07 October, 2025
Market Authorisation Date: 07 October, 2021
Treatment: An adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids
Dosage: CAPSULE;ORAL
TAVNEOS family patents
